Our Approach

Ardelyx develops:

  • Innovative, non-systemic, small molecule therapeutics that work exclusively in the GI tract to treat GI and cardio-renal diseases.
  • We have developed a proprietary drug discovery and design platform enabling us, in a rapid and cost-efficient manner, to discover and design novel drug candidates

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

Therapeutic Areas

We are developing our lead product candidate, tenapanor, for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. We are also developing RDX022 for the treatment of high potassium, or hyperkalemia, in kidney and heart disease patients. Ardelyx is also independently advancing several research programs focused in gastrointestinal and cardio-renal diseases.